Yes, for folks who actually work. NEWS FL.ASH -> that leaves you out Mr Lonesome.
Humira $95.6 Billion and Still Going
- Thread starter anonymous
- Start date
-
- Tags
- None
Jeffs visiting Trump at WH In May. Celgene and Regeneron brass will also be there.
Abbott alumni all MEGA PLAYERS TOP PAID PHARMA CEOs
Annual Salary
Jeff Vertex $45.8M
Miles Abbott $16.4M
Ricky Abbvie $15.4M
AbbVie shares surged 1.5% in premarket trade Thursday after the company reported first-quarter profit and revenue beats. Earnings for the latest quarter rose to $1.71 billion, or $1.06 per share, from $1.35 billion, or 83 cents per share, in the year-earlier period. Adjusted earnings-per-share were $1.28, compared with the FactSet consensus of $1.26, Revenue rose to $6.54 billion from $5.96 billion, compared with the FactSet consensus of $6.48 billion. Revenue for AbbVie's Humira came in at $4.12 billion, above the FactSet consensus of $4.07 billion, as did sales of Imbruvica, at $551 million compared with the FactSet consensus of $540 million. The company said it expects adjusted EPS for 2017 of $5.44 to $5.54, compared with the FactSet consensus of $5.49. AbbVie shares have surged 8.4% over the last three months, compared with a 4.0% rise in the S&P 500
$71 and all time high is coming soon.
AbbVie Common Stock
ABBV (NYSE)
$67.19 USD UP 0.45 (0.67%)
May 4
AbbVie Common Stock
ABBV (NYSE)
$67.19 USD UP 0.45 (0.67%)
May 4
5 Things AbbVie / Ricky And Management Just Said That Ya'll Will Want to Know !!!!!!!!!
Top AbbVie executives talk about protecting Humira, tax reform, and other key topics at the Deutsche Bank healthcare conference.
Keith Speights
(TMFFishBiz)
May 3, 2017 at 3:43PM
What's next for AbbVie (NYSE:ABBV)?
That was the underlying theme for a question-and-answer session with two senior AbbVie executives at the Deusche Bank healthcare conference on Wednesday. Bill Chase, AbbVie's CFO, and Scott Brun, vice president of AbbVie Ventures, spoke candidly about what might be around the corner for the big biotech. Here are five things they said that you'll want to know.
IMAGE SOURCE: GETTY IMAGES.
1. Defending Humira
Humira continues to be the top moneymaker for AbbVie. In the first quarter, the autoimmune disease drug generated sales of $4.1 billion -- 63% of the company's total revenue. With Humira so important to AbbVie's fortunes, there is some angst among investors about the multiple challengers trying to dethrone the tremendously successful drug.
Bill Chase brought up the next development that could increase uncertainty even more: the inter partes review (IPR) filed by Coherus BioSciences (NASDAQ:CHRS) seeking invalidation of AbbVie's '619 patent for Humira. Chase noted that a ruling on this IPR is expected later this month. He admitted that "statistically what happens in an IPR hearing" is that the challenger prevails.
According to Chase, though, AbbVie remains confident in its intellectual property defense for Humira even if Coherus wins in the IPR hearing. He stressed that the value of AbbVie's intellectual property strategy "is in the totality of patents and not in any one patent going through IPR."
Chase pointed to AbbVie's ongoing battle with Amgen (NASDAQ:AMGN), which won U.S. approval for a Humira biosimilar in 2016. He stated that Amgen is a "very competent company" but that its product infringes on 61 Humira patents -- and AbbVie plans to assert its rights to all of them.
The court trial with Amgen has been set to begin in November 2019, which Chase said gives an idea about the timelines that are typical for intellectual property litigation. He reiterated that AbbVie continues to believe that it will be able to successfully protect Humira from U.S. competition through 2022.
2. Competition for Imbruvica
What about competition for AbbVie's No. 2 drug in terms of sales, Imbruvica? Scott Brun expressed confidence, saying the company has "established such a beachhead of data and clinical experience that it will be hard for any competitor to really overcome that lead."
Brun acknowledged that one potential rival to Imbruvica has received considerable attention -- AstraZeneca's (NYSE:AZN) acalabrutinib. He said that AbbVie doesn't see any significant differences in efficacy between AstraZeneca's BTK inhibitor and Imbruvica.
As for safety, Brun noted more cases of atrial fibrillation have been seen in additional reviews of data from acalabrutinib, which he said was not significantly different from Imbruvica. He added that "the ability of the competitor to be able to show materially different safety rates will be very challenging, especially with the size of the study they've got going on."
3. Mergers and acquisitions
Don't expect anything big on the merger and acquisition (M&A) front from AbbVie anytime soon. Bill Chase said that there's "not a compelling need to buy another platform through large M&A." He indicated that the Pharmacyclics and Stemcentrx acquisitions made by AbbVie last year have given the company the assets and clinical expertise it sought. He said that AbbVie didn't have plans to "rush out to add another franchise."
However, Chase noted that there's always a need to add to the pipeline for any drugmaker. Brun added that AbbVie has been making a number of pre-clinical deals to boost its pipeline that don't get a lot of attention.
IMAGE SOURCE: GETTY IMAGES.
4. Pipeline potential
Among the first words out of Bill Chase's mouth at the Deutsche Bank conference was the comment that AbbVie "has one of the most attractive pipelines in the industry." He stated that the company expects to have 20 new assets in place by 2020.
Scott Brun spoke about two especially promising pipeline candidates -- Rova-T and ABT-494. He stressed that there is no competition between Rova-T and immuno-oncology (I-O) therapies. Brun noted that AbbVie is working with combinations of Rova-T and I-O drugs, although there won't be any data readouts from those studies this year.
JAK1 inhibitor ABT-494, however, will begin data readouts beginning next month from a late-stage study targeting treatment of rheumatoid arthritis. Brun said that AbbVie believes the experimental drug could be best in class. He added that the design of the company's studies for ABT-494 should help avoid problems that some think led to the Food and Drug Administration's surprising issuance of a complete response letter (CRL) for Lilly and Incyte's baricitinib.
5. Tax reform (YUGE)
Chase said that AbbVie is "optimistic and encouraged" about the prospects for U.S. tax reform, especially that there could be major changes relatively quickly. While the company would like to have tax rates in the U.S. as low as in some other countries, Chase said that changes that would allow repatriation of overseas cash at lower tax rates would be most important to AbbVie.
What would AbbVie do with the extra cash if tax reform passes? The company's shareholders should like Chase's response. He said that AbbVie probably wouldn't make a large acquisition or pay off its debt. Instead, Chase thinks the company would find the best ways to get cash back into shareholders' hands -- perhaps in the form of even higher dividends.
Top AbbVie executives talk about protecting Humira, tax reform, and other key topics at the Deutsche Bank healthcare conference.
Keith Speights
(TMFFishBiz)
May 3, 2017 at 3:43PM
What's next for AbbVie (NYSE:ABBV)?
That was the underlying theme for a question-and-answer session with two senior AbbVie executives at the Deusche Bank healthcare conference on Wednesday. Bill Chase, AbbVie's CFO, and Scott Brun, vice president of AbbVie Ventures, spoke candidly about what might be around the corner for the big biotech. Here are five things they said that you'll want to know.
IMAGE SOURCE: GETTY IMAGES.
1. Defending Humira
Humira continues to be the top moneymaker for AbbVie. In the first quarter, the autoimmune disease drug generated sales of $4.1 billion -- 63% of the company's total revenue. With Humira so important to AbbVie's fortunes, there is some angst among investors about the multiple challengers trying to dethrone the tremendously successful drug.
Bill Chase brought up the next development that could increase uncertainty even more: the inter partes review (IPR) filed by Coherus BioSciences (NASDAQ:CHRS) seeking invalidation of AbbVie's '619 patent for Humira. Chase noted that a ruling on this IPR is expected later this month. He admitted that "statistically what happens in an IPR hearing" is that the challenger prevails.
According to Chase, though, AbbVie remains confident in its intellectual property defense for Humira even if Coherus wins in the IPR hearing. He stressed that the value of AbbVie's intellectual property strategy "is in the totality of patents and not in any one patent going through IPR."
Chase pointed to AbbVie's ongoing battle with Amgen (NASDAQ:AMGN), which won U.S. approval for a Humira biosimilar in 2016. He stated that Amgen is a "very competent company" but that its product infringes on 61 Humira patents -- and AbbVie plans to assert its rights to all of them.
The court trial with Amgen has been set to begin in November 2019, which Chase said gives an idea about the timelines that are typical for intellectual property litigation. He reiterated that AbbVie continues to believe that it will be able to successfully protect Humira from U.S. competition through 2022.
2. Competition for Imbruvica
What about competition for AbbVie's No. 2 drug in terms of sales, Imbruvica? Scott Brun expressed confidence, saying the company has "established such a beachhead of data and clinical experience that it will be hard for any competitor to really overcome that lead."
Brun acknowledged that one potential rival to Imbruvica has received considerable attention -- AstraZeneca's (NYSE:AZN) acalabrutinib. He said that AbbVie doesn't see any significant differences in efficacy between AstraZeneca's BTK inhibitor and Imbruvica.
As for safety, Brun noted more cases of atrial fibrillation have been seen in additional reviews of data from acalabrutinib, which he said was not significantly different from Imbruvica. He added that "the ability of the competitor to be able to show materially different safety rates will be very challenging, especially with the size of the study they've got going on."
3. Mergers and acquisitions
Don't expect anything big on the merger and acquisition (M&A) front from AbbVie anytime soon. Bill Chase said that there's "not a compelling need to buy another platform through large M&A." He indicated that the Pharmacyclics and Stemcentrx acquisitions made by AbbVie last year have given the company the assets and clinical expertise it sought. He said that AbbVie didn't have plans to "rush out to add another franchise."
However, Chase noted that there's always a need to add to the pipeline for any drugmaker. Brun added that AbbVie has been making a number of pre-clinical deals to boost its pipeline that don't get a lot of attention.
IMAGE SOURCE: GETTY IMAGES.
4. Pipeline potential
Among the first words out of Bill Chase's mouth at the Deutsche Bank conference was the comment that AbbVie "has one of the most attractive pipelines in the industry." He stated that the company expects to have 20 new assets in place by 2020.
Scott Brun spoke about two especially promising pipeline candidates -- Rova-T and ABT-494. He stressed that there is no competition between Rova-T and immuno-oncology (I-O) therapies. Brun noted that AbbVie is working with combinations of Rova-T and I-O drugs, although there won't be any data readouts from those studies this year.
JAK1 inhibitor ABT-494, however, will begin data readouts beginning next month from a late-stage study targeting treatment of rheumatoid arthritis. Brun said that AbbVie believes the experimental drug could be best in class. He added that the design of the company's studies for ABT-494 should help avoid problems that some think led to the Food and Drug Administration's surprising issuance of a complete response letter (CRL) for Lilly and Incyte's baricitinib.
5. Tax reform (YUGE)
Chase said that AbbVie is "optimistic and encouraged" about the prospects for U.S. tax reform, especially that there could be major changes relatively quickly. While the company would like to have tax rates in the U.S. as low as in some other countries, Chase said that changes that would allow repatriation of overseas cash at lower tax rates would be most important to AbbVie.
What would AbbVie do with the extra cash if tax reform passes? The company's shareholders should like Chase's response. He said that AbbVie probably wouldn't make a large acquisition or pay off its debt. Instead, Chase thinks the company would find the best ways to get cash back into shareholders' hands -- perhaps in the form of even higher dividends.
You could layoff the local lazy slug Humira rep and double sales if you went to straight mail order
5 Things AbbVie / Ricky And Management Just Said That Ya'll Will Want to Know !!!!!!!!!
Top AbbVie executives talk about protecting Humira, tax reform, and other key topics at the Deutsche Bank healthcare conference.
Keith Speights
(TMFFishBiz)
May 3, 2017 at 3:43PM
What's next for AbbVie (NYSE:ABBV)?
That was the underlying theme for a question-and-answer session with two senior AbbVie executives at the Deusche Bank healthcare conference on Wednesday. Bill Chase, AbbVie's CFO, and Scott Brun, vice president of AbbVie Ventures, spoke candidly about what might be around the corner for the big biotech. Here are five things they said that you'll want to know.
IMAGE SOURCE: GETTY IMAGES.
1. Defending Humira
Humira continues to be the top moneymaker for AbbVie. In the first quarter, the autoimmune disease drug generated sales of $4.1 billion -- 63% of the company's total revenue. With Humira so important to AbbVie's fortunes, there is some angst among investors about the multiple challengers trying to dethrone the tremendously successful drug.
Bill Chase brought up the next development that could increase uncertainty even more: the inter partes review (IPR) filed by Coherus BioSciences (NASDAQ:CHRS) seeking invalidation of AbbVie's '619 patent for Humira. Chase noted that a ruling on this IPR is expected later this month. He admitted that "statistically what happens in an IPR hearing" is that the challenger prevails.
According to Chase, though, AbbVie remains confident in its intellectual property defense for Humira even if Coherus wins in the IPR hearing. He stressed that the value of AbbVie's intellectual property strategy "is in the totality of patents and not in any one patent going through IPR."
Chase pointed to AbbVie's ongoing battle with Amgen (NASDAQ:AMGN), which won U.S. approval for a Humira biosimilar in 2016. He stated that Amgen is a "very competent company" but that its product infringes on 61 Humira patents -- and AbbVie plans to assert its rights to all of them.
The court trial with Amgen has been set to begin in November 2019, which Chase said gives an idea about the timelines that are typical for intellectual property litigation. He reiterated that AbbVie continues to believe that it will be able to successfully protect Humira from U.S. competition through 2022.
2. Competition for Imbruvica
What about competition for AbbVie's No. 2 drug in terms of sales, Imbruvica? Scott Brun expressed confidence, saying the company has "established such a beachhead of data and clinical experience that it will be hard for any competitor to really overcome that lead."
Brun acknowledged that one potential rival to Imbruvica has received considerable attention -- AstraZeneca's (NYSE:AZN) acalabrutinib. He said that AbbVie doesn't see any significant differences in efficacy between AstraZeneca's BTK inhibitor and Imbruvica.
As for safety, Brun noted more cases of atrial fibrillation have been seen in additional reviews of data from acalabrutinib, which he said was not significantly different from Imbruvica. He added that "the ability of the competitor to be able to show materially different safety rates will be very challenging, especially with the size of the study they've got going on."
3. Mergers and acquisitions
Don't expect anything big on the merger and acquisition (M&A) front from AbbVie anytime soon. Bill Chase said that there's "not a compelling need to buy another platform through large M&A." He indicated that the Pharmacyclics and Stemcentrx acquisitions made by AbbVie last year have given the company the assets and clinical expertise it sought. He said that AbbVie didn't have plans to "rush out to add another franchise."
However, Chase noted that there's always a need to add to the pipeline for any drugmaker. Brun added that AbbVie has been making a number of pre-clinical deals to boost its pipeline that don't get a lot of attention.
IMAGE SOURCE: GETTY IMAGES.
4. Pipeline potential
Among the first words out of Bill Chase's mouth at the Deutsche Bank conference was the comment that AbbVie "has one of the most attractive pipelines in the industry." He stated that the company expects to have 20 new assets in place by 2020.
Scott Brun spoke about two especially promising pipeline candidates -- Rova-T and ABT-494. He stressed that there is no competition between Rova-T and immuno-oncology (I-O) therapies. Brun noted that AbbVie is working with combinations of Rova-T and I-O drugs, although there won't be any data readouts from those studies this year.
JAK1 inhibitor ABT-494, however, will begin data readouts beginning next month from a late-stage study targeting treatment of rheumatoid arthritis. Brun said that AbbVie believes the experimental drug could be best in class. He added that the design of the company's studies for ABT-494 should help avoid problems that some think led to the Food and Drug Administration's surprising issuance of a complete response letter (CRL) for Lilly and Incyte's baricitinib.
5. Tax reform (YUGE)
Chase said that AbbVie is "optimistic and encouraged" about the prospects for U.S. tax reform, especially that there could be major changes relatively quickly. While the company would like to have tax rates in the U.S. as low as in some other countries, Chase said that changes that would allow repatriation of overseas cash at lower tax rates would be most important to AbbVie.
What would AbbVie do with the extra cash if tax reform passes? The company's shareholders should like Chase's response. He said that AbbVie probably wouldn't make a large acquisition or pay off its debt. Instead, Chase thinks the company would find the best ways to get cash back into shareholders' hands -- perhaps in the form of even higher dividends.
Positive news and projections.
Coherus had a small victory today. The odds of launching a bio Humira by 2019 are slim to none. AbbVie’s extensive patent estate extends into 2030’. Only an at-risk launch would over come this but is a dangerous move
Reputation Institute named AbbVie the most reputable pharmaceutical company in today’s release of its annual Global Pharma RepTrak®.
The study is based on over 16,500 reputation ratings collected during January and February 2017 among the general public in 8 key markets: Brazil, Canada, France, Italy, Germany, Spain, UK and US.
The reputation of the pharmaceutical industry is improving and is now at a strong level with the general public. Overall, the industry earned a strong RepTrak® score of 71.8, up from 68.2 in 2016. 44% of respondents viewed the industry as having an excellent reputation with a 7% point increase compared to 2016, while 26% perceived it as weak or poor, down from 35% in 2016. “The strong reputation results come as a surprise to many, who expect the general public to be very negative towards the pharmaceutical companies. However, the reputation data tells a different story,” says Kasper Ulf Nielsen, Executive Partner of Reputation Institute. “We see that the general public actually has strong positive feelings about the individual pharmaceutical companies which they see as delivering on core expectations within products and services, innovation, and leadership. This does not match the media coverage, which is very negative, but serves as a good reminder that media coverage does not equal reputation. Reputation is the perception people have, and that is what is captured in the RepTrak® study.”
The Pharma RepTrak® measures the perception of 17 pharmaceutical companies on overall reputation as well as the seven rational dimensions of reputation: products / services, innovation, workplace, governance, citizenship, leadership and performance. Each company is measured by the general public who are somewhat or very familiar with the company.
The top 10 companies in the 2017 Global Pharma RepTrak® are:
1. AbbVie
2. Novo Nordisk
3. Takeda
4. Roche
5. Janssen Pharmaceuticals
6. Gilead Sciences
7. Bayer
8. MSD / Merck & Co
9. Sanofi
10. Eli Lilly
AbbVie tops the reputation ranking and saw a strong improvement of 5.3 RepTrak® points since last year. “Since the company’s inception less than five years ago, we have worked to raise a better understanding of AbbVie among our key stakeholders,” said Laura Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary, AbbVie. “We are pleased that these efforts have resonated with our global audience and driven greater understanding of who we are and what we stand for as a company.”
Investing in a strong reputation pays off. A 5-point increase in reputation results in a 9% increase in recommendation. The benefit of a strong reputation is seen for AbbVie, Novo Nordisk, and Takeda, where 54% of the general public would definitely recommend these companies, compared to only 44% who would do the same for Pfizer and GSK. “In a world where word of mouth is becoming more and more critical, reputation is proving to be a key driver of business success, and that’s why the leading companies are actively measuring and managing it,” says Kasper Ulf Nielsen, Executive Partner at Reputation Institute.
Within the 7 dimensions of reputation AbbVie took the top spot within Workplace, Governance and Citizenship while Novo Nordisk won on the dimensions of Products / Services and Innovation. Bayer was rated as the best company within Financial Performance and Leadership.
The perceptions of the pharmaceutical companies are improving across all seven dimensions of reputation placing 5 of the 7 dimensions in the strong tier. The strongest perception is for Financial Performance followed by Products / Services, Leadership, and Innovation. Governance and Citizenship are the only dimensions, which are still rated in the average tier with scores of 69.2 and 69.5, respectively. Only 1-4% of people hold negative views of the companies across the 7 dimensions, which explain the improvement in reputation overall. However, some individual companies are still struggling with weak perceptions in specific markets, and they are falling further behind as the rest of the industry is improving.
To learn more about the individual results download the Pharma RepTrak® report here: https://www.reputationinstitute.com/Global-Pharma
About Reputation Institute:
Reputation Institute’s RepTrak® methodology is the gold standard in the science of reputation. Reputation Institute helps global companies unlock the power of their reputations for competitive advantage. Reputation Institute has conducted research over the last 20 years on 7,000 companies across 40 countries developing the largest global normative database in the world on reputation management, KPI’s, benchmarks, metrics and best practices.
The study is based on over 16,500 reputation ratings collected during January and February 2017 among the general public in 8 key markets: Brazil, Canada, France, Italy, Germany, Spain, UK and US.
The reputation of the pharmaceutical industry is improving and is now at a strong level with the general public. Overall, the industry earned a strong RepTrak® score of 71.8, up from 68.2 in 2016. 44% of respondents viewed the industry as having an excellent reputation with a 7% point increase compared to 2016, while 26% perceived it as weak or poor, down from 35% in 2016. “The strong reputation results come as a surprise to many, who expect the general public to be very negative towards the pharmaceutical companies. However, the reputation data tells a different story,” says Kasper Ulf Nielsen, Executive Partner of Reputation Institute. “We see that the general public actually has strong positive feelings about the individual pharmaceutical companies which they see as delivering on core expectations within products and services, innovation, and leadership. This does not match the media coverage, which is very negative, but serves as a good reminder that media coverage does not equal reputation. Reputation is the perception people have, and that is what is captured in the RepTrak® study.”
The Pharma RepTrak® measures the perception of 17 pharmaceutical companies on overall reputation as well as the seven rational dimensions of reputation: products / services, innovation, workplace, governance, citizenship, leadership and performance. Each company is measured by the general public who are somewhat or very familiar with the company.
The top 10 companies in the 2017 Global Pharma RepTrak® are:
1. AbbVie
2. Novo Nordisk
3. Takeda
4. Roche
5. Janssen Pharmaceuticals
6. Gilead Sciences
7. Bayer
8. MSD / Merck & Co
9. Sanofi
10. Eli Lilly
AbbVie tops the reputation ranking and saw a strong improvement of 5.3 RepTrak® points since last year. “Since the company’s inception less than five years ago, we have worked to raise a better understanding of AbbVie among our key stakeholders,” said Laura Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary, AbbVie. “We are pleased that these efforts have resonated with our global audience and driven greater understanding of who we are and what we stand for as a company.”
Investing in a strong reputation pays off. A 5-point increase in reputation results in a 9% increase in recommendation. The benefit of a strong reputation is seen for AbbVie, Novo Nordisk, and Takeda, where 54% of the general public would definitely recommend these companies, compared to only 44% who would do the same for Pfizer and GSK. “In a world where word of mouth is becoming more and more critical, reputation is proving to be a key driver of business success, and that’s why the leading companies are actively measuring and managing it,” says Kasper Ulf Nielsen, Executive Partner at Reputation Institute.
Within the 7 dimensions of reputation AbbVie took the top spot within Workplace, Governance and Citizenship while Novo Nordisk won on the dimensions of Products / Services and Innovation. Bayer was rated as the best company within Financial Performance and Leadership.
The perceptions of the pharmaceutical companies are improving across all seven dimensions of reputation placing 5 of the 7 dimensions in the strong tier. The strongest perception is for Financial Performance followed by Products / Services, Leadership, and Innovation. Governance and Citizenship are the only dimensions, which are still rated in the average tier with scores of 69.2 and 69.5, respectively. Only 1-4% of people hold negative views of the companies across the 7 dimensions, which explain the improvement in reputation overall. However, some individual companies are still struggling with weak perceptions in specific markets, and they are falling further behind as the rest of the industry is improving.
To learn more about the individual results download the Pharma RepTrak® report here: https://www.reputationinstitute.com/Global-Pharma
About Reputation Institute:
Reputation Institute’s RepTrak® methodology is the gold standard in the science of reputation. Reputation Institute helps global companies unlock the power of their reputations for competitive advantage. Reputation Institute has conducted research over the last 20 years on 7,000 companies across 40 countries developing the largest global normative database in the world on reputation management, KPI’s, benchmarks, metrics and best practices.
Abbv has grossly underperformed the SPX over the last 5 yrs and Humira reps are lazy ass wankers.
Trust That Bitch!
Trust That Bitch!
My 401K just hit $1.25 Million. All the micro managing bs at Abbott and here was well worth it. 25 year run and retired last month at 55. Thank you Mr. White !
I am close to getting out and it's the stock that made it tolerable to stay here.
Looking back over the past 10 years alone, I bet I faked 150 speaker programs alone just so I could get my speaker paid and could keep management off my back.
Looking back over the past 10 years alone, I bet I faked 150 speaker programs alone just so I could get my speaker paid and could keep management off my back.
An Ocean County man snagged a 1500 pound female great white while bluefish fishing with friends. On May 29th about two miles off Long Beach Island. ******** A former Pharmaceutical executive in his 43 foot pleasure craft battled the shark for 45 minutes before cutting the steel leader as the fish was reeled within three feet of the boat.
Abbie buys doctors (speakers) by getting them to speak in the same territory over and over to the same (mainly) staff just to make them write more. It's ridiculous. Someone needs to report this to the FDA